Latest Sales Growth News

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Meridian Energy has secured a draft decision allowing greater access to Lake Pūkaki’s hydro storage contingent reserves, with plans to moderate usage amid supply risk concerns.

Xenitra Limited’s OPAL Real World Asset tokenised sales ecosystem has accelerated rapidly, crossing $1.1 million in product sales and onboarding over 400 distribution partners within seven weeks, signalling strong traction in Greater China.

OMG Group's net sales hit approximately $6.2 million on a moving annual total basis, marking a 57% increase year-on-year, driven by ecommerce growth and key international distribution deals.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

Burger Fuel Group reported a 91.8% surge in net profit to NZD 1.97 million for FY26, driven by sales growth, reduced legal costs, and a one-off store sale gain, despite geopolitical headwinds in the Middle East.

Cooks Coffee Company reported a 22.8% jump in group store sales and a 27% rise in normalised EBITDA for FY26, driven by strong UK and Ireland growth and new international franchise agreements.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.

Immuron Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, confirming no undisclosed information but pointing to a recent CEO presentation as a possible driver.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Metro Performance Glass has significantly improved its financial footing in FY26, cutting net debt by more than half and boosting EBITDA before significant items to $18.2 million despite subdued markets in New Zealand and Australia.